



Par Pharmaceutical  
300 Tice Blvd, Suite 230  
Woodcliff Lake, NJ 07677

www.parpharm.com

May 25, 2023

doi.healthcareanalytics@ins.nh.gov

Notice of a New Prescription Drug Pursuant to N.H. Rev. Stat. § 318:67

Dear New Hampshire Insurance Department,

Par Pharmaceutical, Inc. ("Par") is issuing this notice pursuant to N.H. Rev. Stat. § 318:67, which asks prescription drug manufacturers to provide the State of New Hampshire Insurance Department (the "NHID") written notice within three calendar days of releasing a drug in the commercial market whose wholesale acquisition cost ("WAC") exceeds the threshold set for a specialty drug under the Medicare Part D Program.

On May 25, 2023, Par informed potential customers the following drug product was available for order:

NDC #	Product Description
10370-0366-11	Topiramate ER Caps 50mg 30s
10370-0366-01	Topiramate ER Caps 50mg 100s

On or about May 25, 2023, Par intends to commence shipping the aforementioned drug product to its third party customers.

The WAC for the drug product identified above exceeds the threshold set for a specialty drug under the Medicare Part D Program. Please note that the WAC-related information provided in this notice may be subject to change.

New Hampshire Insurance Department Bulletin INS 20-017-AB (June 23, 2020) defines "date of commercial availability" as "the commercial launch date or the day the manufacturer begins selling and shipping the product."

In the event New Hampshire HB 703 and the laws it implements, including N.H. Rev. Stat. § 318:67, are found invalid, Par reserves all of its legal rights. In issuing this notice in an attempt to comply with N.H. Rev. Stat. § 318:67, Par does not waive any legal claims or legal rights related to potential constitutional defects with New Hampshire HB 703.

Sincerely,

Scott Sims, SVP & GM Injectable Solutions and Generics  
Par Pharmaceutical an endo company